Table 3.
Frequency of nodal metastases by risk factorsa.
| Risk Factor | Pelvic
|
Aortic
|
|||||
|---|---|---|---|---|---|---|---|
| N+ | % | p-Value | N+ | % | p-Value | ||
| Histology | <0.001 | <0.001 | |||||
| Endometrioid, grade 1 | (N = 1516) | 60 | 4.0 | 30 | 2.0 | ||
| Endometrioid, grade 2 | (N = 1129) | 82 | 7.3 | 41 | 3.6 | ||
| Endometrioid, grade 2 | (N = 580) | 103 | 17.8 | 52 | 9.0 | ||
| Serous (SER) | (N = 805) | 201 | 25.0 | 141 | 17.5 | ||
| Clear cell (CLC) | (N = 274) | 55 | 20.1 | 34 | 12.4 | ||
| Carcinosarcoma (CLC) | (N = 322) | 68 | 21.1 | 49 | 15.2 | ||
| Mixed, nos. (OMX) | (N = 318) | 64 | 20.1 | 42 | 13.2 | ||
| Other (OTH) | (N = 188) | 29 | 15.4 | 24 | 12.8 | ||
| Myometrial invasion | <0.001 | <0.001 | |||||
| Endometrium only (EN) | (N = 1184) | 31 | 2.6 | 14 | 1.2 | ||
| Inner half (IN) | (N = 2477) | 172 | 6.9 | 93 | 3.8 | ||
| Outer half (OU) | (N = 1304) | 361 | 27.7 | 229 | 17.6 | ||
| Serosa (SE) | (N = 156) | 95 | 60.9 | 74 | 47.4 | ||
| Peritoneal cytology | <0.001 | <0.001 | |||||
| Negative | (N = 4364) | 459 | 10.5 | 266 | 6.1 | ||
| Positive | (N = 532) | 169 | 31.8 | 121 | 22.7 | ||
| Adnexal involvement | <0.001 | <0.001 | |||||
| Negative | (N = 4629) | 464 | 10.0 | 261 | 5.6 | ||
| Positive | (N = 475) | 195 | 41.0 | 149 | 31.4 | ||
| Other extra-uterine metastasis | <0.001 | <0.001 | |||||
| Negative | (N = 4567) | 404 | 8.9 | 237 | 5.2 | ||
| Positive | (N = 565) | 258 | 45.7 | 176 | 31.2 | ||
| Lympho-vascular space involvement | <0.001 | <0.001 | |||||
| Negative | (N = 3722) | 151 | 4.1 | 85 | 2.3 | ||
| Positive | (N = 1323) | 496 | 37.5 | 315 | 23.8 | ||
| Menopausal status | <0.001 | <0.001 | |||||
| Pre-menopause | (N = 389) | 30 | 7.7 | 18 | 4.6 | ||
| Post-menopause | (N = 3366) | 441 | 13.1 | 289 | 8.6 | ||
a
Patients with both pelvic and aortic node status and variable information.